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ABSTRACT  103 
Histone lysine methylation mediated by mixed-lineage leukemia (MLL) proteins, has 104 
emerged as critical in the regulation of gene expression, genomic stability, cell cycle 105 
and nuclear architecture. Although postulated to be essential for normal 106 
development, little is known about the specific functions of the different MLL lysine 107 
methyltransferases. Here, we report heterozygous mutations in KMT2B (MLL4) in 108 
27 unrelated individuals with a complex progressive childhood-onset dystonia, often 109 
associated with a typical facial appearance and characteristic findings on brain 110 
magnetic resonance imaging. Over time the majority developed prominent cervical, 111 
cranial and laryngeal dystonia. Marked clinical benefit was observed following deep 112 
brain stimulation (DBS), leading to even restoration of independent ambulation in 113 
some cases. Decreased gene expression of THAP1 and TOR1A was evident in 114 
cultured skin fibroblasts from subjects with KMT2B mutations, with reduced THAP1 115 
protein levels on immunoblotting. Analysis of cerebrospinal fluid from KMT2B 116 
mutation-positive patients revealed markedly reduced levels of dopamine 2 receptor 117 
protein, with increased tyrosine hydroxylase levels. Our findings highlight a major 118 
new, clinically recognizable, and potentially treatable form of genetic dystonia, 119 
demonstrating the crucial role of KMT2B in the physiological control of voluntary 120 
movement.121 
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 122 
INTRODUCTION 123 
The control of voluntary movement is governed by interactive neural networks 124 
within the brain, involving the basal ganglia, sensorimotor cortex, cerebellum and 125 
thalamus1. Disruption of such pathways can lead to the development of a variety of 126 
motor disorders. Dystonia is one such movement disorder characterized by 127 
sustained or intermittent muscle contractions, causing abnormal, often repetitive 128 
movements and postures affecting the limbs, trunk, neck and face. Dystonic 129 
movements are typically patterned, twisting, and may be tremulous, often initiated 130 
or worsened by voluntary action and associated with overflow muscle activation2. 131 
Dystonia is the 3rd most commonly reported movement disorder worldwide1. It is 132 
described in a broad spectrum of genetic and acquired disorders, either in isolation 133 
or combined with other neurological and systemic features2. The precise 134 
pathophysiological processes remain yet to be fully elucidated, but defective 135 
dopaminergic signaling is thought to play an important role in many forms of 136 
isolated and complex dystonia1,3-5. 137 
Despite genetic advances, the underlying cause remains elusive for a significant 138 
proportion of individuals with childhood-onset dystonia, hindering future 139 
prognostication and treatment strategies6. Here we report 27 individuals with an 140 
early-onset, complex, combined progressive dystonia associated with mono-allelic 141 
mutations in KMT2B (MLL4, OMIM *606834). KMT2B encodes a lysine histone 142 
methyltransferase, involved in H3K4 methylation, an important epigenetic 143 
modification associated with active gene transcription.144 
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 145 
RESULTS 146 
Chromosomal microdeletions and intragenic KMT2B mutations in early-onset 147 
dystonia 148 
We identified a cohort of 34 patients with undiagnosed childhood-onset dystonia for 149 
further molecular genetic investigation ([Online Methods, Supplementary Table 1, 150 
Supplementary Fig. 1). On routine diagnostic testing, one case (Patient 1) was 151 
found to have a microdeletion at 19q13.12 of undetermined significance7. 152 
Diagnostic chromosomal microarray was therefore undertaken in as many patients 153 
as logistically possible from this cohort (n=20) and overlapping microdeletions were 154 
detected in 5 more children (Supplementary Table 1, Patients 2-6). Using 155 
established networks (Online Methods, Supplementary Fig. 1), 4 more cases 156 
(Patients 7-10) with microdeletions were identified. In total, 10 patients (Patients 1-157 
10) were found to have overlapping heterozygous interstitial microdeletions at 158 
19q13.11-19q13.12 (Table 1a, Fig.1). Deletions detected on diagnostic microarray 159 
studies were confirmed by standard established laboratory protocols and confirmed 160 
de novo where parental testing was possible (Supplementary Table 2a). The 161 
smallest region of overlap extended from 36,191,100-36,229,548bp 162 
(GRCh37/Hg19), and contained two HUGO Gene Nomenclature Committee 163 
curated genes, ZBTB32 (zinc finger and BTB domain containing 32) and KMT2B 164 
(MLL4) (Fig. 1).  165 
Of the remaining 28 patients from the original cohort, we undertook research exome 166 
(n=6) and genome sequencing (n=9) in 15 patients (Online Methods). 167 
Heterozygous variants of KMT2B were identified in 6/15 cases (Patients 13, 14, 17, 168 
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21, 22, 27). Subsequent Sanger sequencing of KMT2B in the other 13/28 169 
individuals from the original cohort detected one more mutation-positive case 170 
(Patient 16). A further 10 cases (Patients 11, 12, 15, 18, 19, 20, 23, 24, 25, 26a) 171 
were ascertained through both national and international collaborators (Online 172 
Methods, Supplementary Fig. 1). In total, 17 patients with intragenic heterozygous 173 
KMT2B variants were identified, harboring frameshift insertions (n=1), frameshift 174 
deletions (n=6), splice site (n=1), stop-gain (n=2) and missense (n=7) mutations 175 
(Fig.1). All KMT2B mutations were confirmed on Sanger sequencing and parental 176 
segregation studies completed where DNA was available (Table 1a, Fig. 1, 177 
Supplementary Table 2a, Supplementary Fig. 2). No pathogenic variants in 178 
either ZBTB32 or other known disease-associated genes (including genes causing 179 
clinically similar forms of dystonia) were otherwise identified in patients who had 180 
whole exome or genome sequencing. In the remaining patients, where further 181 
genetic testing was possible, mutations in TOR1A, THAP1 and GNAL were 182 
excluded by diagnostic single gene testing, multiple gene panel testing or research 183 
Sanger sequencing (Supplementary Table 3). 184 
Phenotypic characterization of patients with KMT2B mutations 185 
Overall, we identified 27 patients (current age 6-40 years, 14 female, 13 male) with 186 
childhood-onset progressive dystonia (Table 1a, Table 1b, Supplementary Table 187 
4, Supplementary Videos 1-7). Individuals presented in early childhood (1-9 years, 188 
median age 4 years) with either limb or cranio-cervical dystonia. Clinical 189 
presentation for those with microdeletions, frameshift, splice-site and stop-gain 190 
variants (mean age 4.1 years) occured significantly earlier than for those with 191 
intragenic missense mutations (mean age 6.4 years) (p-value 0.0223) 192 
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(Supplementary Fig. 3a). Most patients (21/27) had lower limb symptoms at 193 
disease onset, leading to foot posturing, toe-walking and gait disturbance (Fig. 2a). 194 
4/27 patients presented initially with upper limb symptoms associated with 195 
abnormal postures (Fig. 2b,c) and dystonic tremor, leading to reduced dexterity 196 
and handwriting difficulties (Supplementary Fig. 4a,b). With increasing age, 197 
cervical symptoms (torticollis, retrocollis) (Fig. 2d,e) and cranial involvement (facial 198 
dystonia, oromandibular involvement with dysarthria/anarthria and difficulties in 199 
chewing/swallowing) became prominent features in the majority of patients. In many 200 
patients, progressively severe dysphonia was suggestive of laryngeal involvement. 201 
None of the patients had airway compromise and videostroboscopy was not 202 
undertaken. Over time, the majority of patients (24/27) developed progressive 203 
generalized dystonia, 2-11 years after initial presentation (Fig. 2f). The dystonia 204 
was persistent in nature, absent in sleep, worsened by voluntary action and 205 
associated with overflow muscle activation. Some patients had dystonic tremor. 206 
Sudden, brief, involuntary muscle jerks, clinically consistent with myoclonus was 207 
evident in 2 cases (Patients 14 and 27). For a few subjects, dystonia was 208 
exacerbated when systemically unwell. Stepwise deterioration following intercurrent 209 
illness was particularly evident in Patient 14, and status dystonicus, triggered by a 210 
urinary tract infection, was reported in Patient 3. 211 
Many patients with KMT2B mutations had further clinical findings. Additional 212 
neurological symptoms and signs were evident in some patients, including 213 
microcephaly, seizures, spasticity and eye movement abnormalities (strabismus, 214 
saccade initiation failure and oculomotor apraxia) (Table 1b). Dysmorphic features 215 
and characteristic facial appearance (elongated face and bulbous nasal tip) (Fig. 216 
2g, Table 1b) were commonly reported. Delay in neurodevelopmental milestones, 217 
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intellectual disability, systemic (dermatological, renal, respiratory) features and 218 
psychiatric symptoms were also present in some individuals (Table 1b, 219 
Supplementary Table 4, Supplementary Fig. 4c). Malignancies were not reported 220 
in any patients. Cerebrospinal fluid (CSF) neurotransmitter analysis was undertaken 221 
in 13 patients revealing no major derangement of monoamine metabolites 222 
(Supplementary Table 5a). Magnetic resonance (MR) imaging revealed a 223 
characteristic signature in 17/22 patients who had imaging sequences suitable for 224 
assessment (Supplementary Table 5b). Subtle symmetrical hypointensity of the 225 
globus pallidi (with a hypointense streak of bilateral globus pallidus externa) was 226 
evident on MR images known to be sensitive to the magnetic resonance 227 
phenomenon of susceptibility (T2*-, susceptibility- and echo-planar imaging b0-228 
diffusion-imaging datasets) (Fig. 3). The mean age at neuroimaging was 229 
significantly lower for patients with MR abnormalities (11.7 years) than for those 230 
with normal brain scans (19.0 years) (p-value 0.0167) (Supplementary Fig. 3b). 231 
Single positron emission tomography using 123I (DaTSCANTM) and 18 FDG-PET-CT 232 
glucose uptake studies, each undertaken in 3 patients, were normal 233 
(Supplementary Table 5b, Supplementary Fig. 4d). 234 
Deep brain stimulation: clinical benefit in KMT2B-dystonia 235 
Overall, medical therapies were not of clinical benefit in this patient cohort. None of 236 
the patients had a sustained response to levodopa treatment, nor other commonly 237 
used anti-dystonic agents (Table 1a). Due to the medically intractable, progressive 238 
nature of disease, 10 patients had symptomatic treatment with bilateral globus 239 
pallidus interna-deep brain stimulation (GPi-DBS) (Table 1a). All showed clinical 240 
benefit with DBS (which was particularly striking in some of the younger patients) 241 
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with overall amelioration of dystonia, improved oromandibular symptoms, better 242 
upper and lower limb function and even restoration of independent ambulation in 243 
some patients. Patient 6 showed significant improvement of torticollis and 244 
retrocollis, as well as in overall function and gait after DBS. Patient 8 showed a 245 
sustained clinical response 6 years after DBS insertion, with improvement of 246 
dystonia, even more evident after replacement of a faulty right DBS lead. Patient 9 247 
had generalized dystonia and could not walk independently pre-DBS. Two weeks 248 
post-DBS insertion he dramatically regained independent ambulation with marked 249 
improvement of dystonic symptoms (Supplementary Video 8). Patient 17 and 21 250 
were predominantly wheelchair-dependent pre-DBS insertion, but both patients 251 
showed restoration of independent walking and improvement of dystonia after DBS 252 
(Supplementary Video 9,10). Patient 19 had improvement in oromandibular 253 
symptoms with DBS. Patient 20 had DBS insertion at age 32 years and although 254 
most benefits were only transient, sustained improvement of foot posture was 255 
reported. Patient 23 had significant amelioration of dystonia symptoms after DBS 256 
insertion. Patient 22, now 9 months post-DBS (Supplementary Video 11) and 257 
Patient 25, 4 months post-DBS have both shown significant gains in hand function 258 
and independent walking with reduction of dystonia. Five patients in the cohort are 259 
now over three years post-surgery, and the observed reduction of dystonia, 260 
restoration of function and prevention of progressive disability is evidence of 261 
sustained clinical benefit. 262 
KMT2B is constrained for missense and predicted protein truncating variants 263 
Four individuals (Patient 13, 14, 17 and 21) had whole genome sequencing as part 264 
of the NIHR-funded BioResource-Rare Disease project. Enrichment analysis was 265 
undertaken in this cohort in order to determine whether predicted protein truncating 266 
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variants (PPTVs) in KMT2B are observed more frequently in patients than would be 267 
expected by chance. Given the size and sequence context of KMT2B, 5.73x10-03 de 268 
novo PPTVs are expected to occur by chance in KMT2B in the subset of the NIHR 269 
BioResource- Rare Diseases cohort who have pediatric onset neurological disease, 270 
but 3 PPTVs are observed. This represents a significant enrichment (p-value 271 
3.12x10-08). Furthermore in ExAC, KMT2B is also highly constrained for PPTVs. In 272 
the ExAC database of 60,706 individuals (Exome Aggregation Consortium (ExAC), 273 
Cambridge, MA (URL: http://exac.broadinstitute.org, accessed July 2016)8, there 274 
are only 5 PPTVs that are not flagged as having dubious variant annotation. All are 275 
extremely rare (4 are found in a single individual and one occurs in 2 individuals). 276 
Given the size and sequence context of the gene, the presence of so few PPTVs in 277 
a cohort of 60,706 individuals reveals KMT2B to be highly constrained for such 278 
variation, providing supportive evidence of its pathogenicity. Regarding variants in 279 
the ExAC database, there are 712 reported non-synonymous changes. Most of 280 
these are rare, as expected for a cohort of this size, and the median CADD score9 281 
for these variants is 22.9. The median CADD score for missense mutations 282 
identified in our KMT2B-dystonia cohort is significantly higher at 29.1 (p-value 283 
0.0001364; Supplementary Table 2b). Furthermore, given the size and sequence 284 
context of KMT2B, 956 missense variants are predicted to occur by chance, 285 
suggesting that KMT2B may also be constrained for missense variation (z=4.06)8.  286 
KMT2B variants are predicted to destabilize protein structure 287 
In silico homology modelling studies were undertaken to generate hypotheses 288 
regarding the predicted effects of mutations on KMT2B structure-function properties 289 
(Supplementary Results). Based on Pfam domain assignments, KMT2B has a 290 
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CXXC zinc finger domain, multiple PHD domains, an F/Y rich N-terminus (FYRN), 291 
FYRC (F/Y rich N-terminus) domain and a C-terminal SET domain (Fig. 4a). The 292 
modelled mutations occurred in residues within the PHD-like, FYRN, SET and 293 
FYRC-SET linking domains (Fig. 4b-d). Evaluation of a number of mutations using 294 
MAESTRO10 and DUET11 suggests change in free energy, with a predicted 295 
structure destabilizing effect (Supplementary Results). 296 
Mutations Phe1662Leu and Gly1652Asp occur within a PHD-like domain (residues 297 
1574-1688), predicted to facilitate interaction with DNA, protein-protein interaction 298 
and recognition of methylated/unmethylated lysines12-14. Extensive hydrophobic 299 
interactions hold the globular structure of this region, which is important for its 300 
function12. Phe1662 is fully buried at the core, stabilizing the structure of this PHD-301 
like domain while Gly1652 is partially buried (Fig. 4b,e,f). Phe1662 is involved in 302 
multiple hydrophobic contacts at the core of the PHD domain, and mutation to 303 
leucine is predicted to cause loss of contacts at the core (Fig. 4g). Gly1652 is 304 
located on a loop (Fig. 4e) and mutation to aspartic acid is predicted to alter surface 305 
charge, with possible effect on the interaction network in the vicinity, involving a 306 
positively charged Arg1635, part of the helix α3 implicated in DNA binding12. 307 
Arg1762 and Leu1781 occur in a FYRN domain. FYRN and FYRC regions, 308 
particularly common in MLL histone methyltransferases, interact to form a compact 309 
structural unit (Fig. 4c,h), important in maintaining the active structure15,16. Arg1762 310 
forms hydrogen bonds with the backbone carboxyls of Arg2463 and Leu2464 of 311 
FYRC domain. Substitution of Arg1762 by cysteine is predicted to abolish these 312 
contacts and hence contribute to destabilization of FYRC-FYRN association. 313 
Leu1781, at the interface between FYRN and FYRC (Fig. 4h,i) is surface exposed 314 
and involved in backbone hydrogen bonds stabilizing the beta sheet formed 315 
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together by the two domains. Mutation to proline is predicted to disrupt the 316 
backbone hydrogen bond at this position, because it lacks one hydrogen bond 317 
donor and its backbone torsion angles are not compatible with that of a beta sheet, 318 
with a predicted destabilizing effect on sheet structure, potentially affecting the 319 
normal association of FYRN and FYRC domains. Arg2517 resides in the region 320 
linking FYRC and SET domains, known to bind WDR5, an effector required for 321 
trimethylation of histone H317, presenting methylated histone H3 substrates to the 322 
MLL complex for further methylation18. Arg2517 is thought to be involved in a salt-323 
bridge interaction with Asp172 of WDR5 (Fig. 4j) and Arg2517Trp is predicted to 324 
lead to loss of this interaction. Ile2674, Tyr2688 and Ile2694 occur in the catalytic 325 
methyltransferase SET domain common to histone lysine methyltransferases. 326 
Ile2674 is buried in the hydrophobic core, adjacent to the catalytic site (Fig. 4d,k). 327 
Mutation to threonine is predicted to lead to loss of contacts at the core of the 328 
domain (due to the shorter side chain) and also introduces a buried polar group 329 
(Fig. 4k,l). Tyr2688Thr occurs at the core of SET domain involving extensive 330 
hydrophobic interactions and a hydrogen bond interaction with Ser2661 (Fig 4m). 331 
The frameshift mutation Tyr2688Thrfs*50 with insertion of 50 additional residues, is 332 
predicted to destabilise the core and affect contacts due to the substitution with a 333 
shorter non-aromatic side-chain. Ile2694 is involved in the extensive hydrophobic 334 
contacts stabilizing the core of this domain. In silico analysis predicts that the 335 
frameshift mutation Ile2694Serfs*44 will disrupt the domain fold and affect 336 
methytransferase activity. 337 
KMT2B is ubiquitously expressed with reduced expression in KMT2B-338 
dystonia 339 
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We confirmed widespread KMT2B expression in a variety of control fetal and adult 340 
human tissues (Fig. 5a). Moreover, KMT2B is ubiquitously expressed in the brain, 341 
with higher expression in the cerebellum than any other region (Fig. 5b). We 342 
ascertained fibroblasts from 4 patients (Patient 2, 13, 14, 16, with either 343 
microdeletions or PPTVs in KMT2B) and detected a statistically significant 344 
decrease in fibroblast KMT2B expression on quantitative RT-PCR when compared 345 
to control fibroblasts (Fig. 5c).  346 
Histone H3K4 methylation is not globally reduced in KMT2B-dystonia  347 
To determine the effect of KMT2B mutations on methylation of lysine 4 on histone 348 
H3 (H3K4 methylation), we assayed tri-methylated H3K4 (H3K4me3) and di-349 
methylated H3K4 (H3K4me2). Immunoblotting of histones extracted from fibroblasts 350 
of Patient 14 and 16 showed no significant reduction in H3K4me3 or H3K4me2 351 
relative to control samples (Fig. 5d, Supplementary Fig. S5a). We used the model 352 
species Dictyostelium discoideum to test the effect of SET domain mutation 353 
Ile2647Thr on in vivo histone methyltransferase activity. The SET domain of 354 
KMT2B shares 56% sequence identity with the Dictyostelium orthologue DdSet1, 355 
and Ile2647 is conserved (corresponding amino acid in Dictyostelium is Ile1447) 356 
(Fig. 1h). DdSet1 is the only H3K4 methyltransferase in Dictyostelium and targeted 357 
knockout of DdSet1 (set1-) results in loss of all methylation at H3K419. We 358 
constitutively expressed wild-type DdSet1 (WT-DdSet1) and mutant-DdSet1 (m-359 
DdSet1), both with N-terminal GFP fusions, in set1- Dictyostelium cells and 360 
compared the resulting levels of H3K4 methylation. Expression of either GFP-WT-361 
DdSet1 or GFP-mDdSet1 in set1- cells resulted in rescue of H3K4 tri-methylation to 362 
wild type levels (Fig. 5e, Supplementary Fig. S5b, S5c). 363 
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Fibroblast THAP1 gene and protein expression is reduced in KMT2B-dystonia 364 
In order to determine whether KMT2B-dystonia is associated with dysregulation of 365 
specific genes implicated in the control of movement, we investigated the 366 
expression profiles of TOR1A and THAP1. Fibroblasts derived from 4 patients 367 
(Patients 2, 13, 14, 16) showed significantly reduced transcript levels of THAP1 and 368 
TOR1A when compared to control fibroblasts (Fig. 5f). Fibroblast immunoblotting 369 
studies showed a statistically significant reduction in THAP1 protein expression in 370 
all 4 patients when compared to control samples (Fig. 5g). A statistically significant 371 
reduction in TOR1A protein level was evident in Patient 14, though not in the other 372 
patients (Fig. 5h).  373 
Abnormal CSF levels of dopaminergic proteins in KMT2B-dystonia  374 
CSF immunoblotting studies were undertaken in two patients for whom samples 375 
were available for research testing (Patient 2 and 16). Both patients had markedly 376 
reduced levels of dopamine 2 receptor (D2R), 56.9% and 59.8% of levels observed 377 
in control CSF (Controls = 1.09±0.21SD, KMT2B patients = 0.64±0.02SD). In 378 
contrast, an increase in tyrosine hydroxylase (TH) levels was seen in both mutation-379 
positive patients (173.3% and 170.9% of levels seen in control CSF) (Controls = 380 
0.52±0.08SD, KMT2B patients = 0.90±0.01SD) (Fig. 5i). 381 
DISCUSSION 382 
We report 27 individuals with heterozygous mutations in the lysine 383 
methyltransferase gene, KMT2B, and define a new genetic movement disorder that 384 
importantly, is amenable to treatment with DBS. Using the current classification 385 
system2, KMT2B-dystonia is defined as an inherited autosomal dominant, complex, 386 
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combined dystonia usually of infantile or childhood-onset. In most patients, the 387 
dystonia is persistent and progressive in nature. The majority of individuals develop 388 
4-limb dystonia with particularly prominent cervical, laryngeal and oromandibular 389 
symptoms. Whilst the majority of patients in this cohort seem to follow this disease 390 
trajectory, we also report atypical cases with relatively little limb involvement and 391 
either mainly oromanibular features (Patient 18) or paroxysmal cervical dystonia 392 
(Patient 26a). 393 
For many patients, KMT2B-dystonia is associated with a number of additional 394 
clinical features, including other neurological symptoms, intellectual disability, 395 
psychiatric co-morbidity, dysmorphia, skin lesions and other systemic signs. Given 396 
the association with active gene expression, is possible that KMT2B could account 397 
for these additional disease features. For Patients 1-10, is also possible that other 398 
genes within their microdeletion could contribute to aspects of their clinical 399 
phenotype. Indeed, cutis aplasia and ectodermal dysplasia have been reported in 400 
patients with more proximal deletions of chromosome 19q13.1120. KMT2B is 401 
therefore a complex dystonia, and affected patients should have close surveillance 402 
of development during childhood, regular neurology assessments, routine 403 
dermatological review and formal neuropsychiatric testing. 404 
In KMT2B-dystonia, the majority of patients had a characteristic pattern on MR 405 
imaging, with very subtle low pallidal signal on T2*-, diffusion- and susceptibility-406 
weighted sequences, particularly affecting the lateral aspect of the globus pallidus 407 
externa (Fig. 3). Although genotype did not appear to influence whether MR 408 
findings were evident, those with abnormal imaging had scans undertaken at a 409 
significantly younger age than those with normal imaging. Indeed, MR abnormalities 410 
could possibly be an age-dependent phenomenon, perhaps becoming less 411 
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apparent with increasing age, as was evident in Patient 22 (Supplementary Table 412 
5b, Supplementary Fig. 3b,c,d). The overall significance of the identified 413 
neuroradiological abnormalities remains unclear. Such radiological findings are 414 
reminiscent of, but much more subtle and different to those reported in classical 415 
Neurodegeneration with Brain Iron Accumulation (NBIA) syndromes21,22. Similar 416 
non-specific features of T2*-weighted hypointensity are increasingly recognized in a 417 
number of other neurological conditions, including Huntington’s disease, TUBB4A-418 
related disorders, GM1 gangliosidosis, alpha-fucosidosis and 419 
mitochondriocytopathies. 420 
In the original UCL-ICH Dystonia cohort, KMT2B mutations were identified in 13/34 421 
(38%) individuals with a relatively homogenous phenotype of early onset 422 
progressive dystonia. In other screened cohorts, mutation detection rates varied 423 
from 1.3-30%, with more cases identified from cohorts that were tightly phenotyped 424 
for dystonia (Supplementary Fig. 1). In screened cases where KMT2B mutations 425 
were not detected, it is likely that these individuals have another underlying etiology 426 
accounting for their symptoms, although it is possible that (i) single/multiple exon 427 
KMT2B deletions and duplications may have been missed on microarray, Sanger 428 
sequencing and whole exome/genome sequencing and (ii) promoter mutations and 429 
deeply intronic KMT2B variants may not have been detected by whole exome and 430 
Sanger sequencing. 431 
The majority of individuals with KMT2B mutations (20/27, Patients 1-20) had either 432 
heterozygous interstitial microdeletions leading to KMT2B haploinsufficiency, or 433 
variants predicted to cause protein truncation, protein elongation, splicing defects or 434 
nonsense-mediated mRNA decay. The remaining 7 patients (Patients 21-27) had 435 
previously unreported non-synonymous variants of KMT2B, all affecting conserved 436 
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residues within key protein domains (Fig. 1c-h), and in silico studies predict 437 
destabilization of protein structure. Notably, initial disease presentation was 438 
significantly earlier in Patients 1-20 than in those with missense variants 439 
(Supplementary Fig. 3a). In KMT2B-dystonia, genotype did not however influence 440 
the rate of symptom evolution, disease severity or response to DBS.  441 
For the majority of patients, KMT2B mutations were confirmed as de novo where 442 
parental testing could be undertaken. In our cohort, 3 patients had missense 443 
mutations that were all maternally inherited (Patient 22, 26a, 27). Given this 444 
observation of maternal inheritance, the possibility of imprinting at the disease locus 445 
was considered, but deemed unlikely, given (i) de novo microdeletions in Patients 2 446 
and 10 occurred on paternally inherited alleles and (ii) there is evidence of bi-allelic 447 
expression of KMT2B single nucleotide polymorphisms in human tissues, including 448 
brain (Supplementary Fig. S6). Importantly, whole exome sequence analysis 449 
undertaken in Patients 22, 26a and 27 did not identify other rare or de novo variants 450 
to account for their disease. Interestingly, Patient 26a inherited p.Arg2517Trp from 451 
his symptomatic mother (26b) who also had (milder) disease symptoms. She 452 
reported gait abnormalities and a progressive inability to run, as well as periodic 453 
paroxysmal upper limb and neck dystonia. She also had a bulbous nasal tip, like 454 
her son (Fig. 2g). In contrast, both mothers of Patients 22 and 27 were clinically 455 
examined, and neither had evidence of a motor phenotype, intellectual disability, 456 
other neurological features, neuropsychiatric symptoms, facial dysmorphia, skin 457 
lesions or other systemic signs. The identification of both symptomatic and 458 
asymptomatic carriers suggests that there may be either “apparent’ incomplete 459 
penetrance, due to parental mosaicism, or true incomplete disease penetrance, a 460 
phenomenon commonly reported in a number of other autosomal dominant genetic 461 
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dystonias23,24. Furthermore, other genetic, epigenetic and environmental modifiers 462 
may also influence disease penetrance and phenotypic presentation in KMT2B-463 
dystonia. 464 
KMT2B encodes an ubiquitously expressed lysine methyltransferase specifically 465 
involved in H3K4 methylation25.26, an important epigenetic modification associated 466 
with active transcription. H3K4me3 is enriched at promoters, marking transcription 467 
start sites of actively transcribed genes, whereas H3K4me1 is associated with 468 
active enhancer sequences27. H3K4me2 is less specifically localized, but may be 469 
enriched at transcription factor binding sites28. Members of the SET/MLL protein 470 
family, including KMT2B, are responsible for the generation of H3K4me1, 471 
H3K4me2, and H3K4me3, essential for gene activation in normal development29. 472 
Using patient-derived fibroblasts and a Dictyostelium discoideum model, we 473 
demonstrated that KMT2B mutations are not associated with widespread alterations 474 
in overall levels of H3K4 methylation. This is not surprising, given that 475 
haploinsufficiency of other MLL family members have not been convincingly shown 476 
to affect global H3K4 levels. The fundamental physiological role of MLL proteins is 477 
however further affirmed by the observation that loss-of-function heterozygous 478 
mutations in MLL-encoding genes are reported in human developmental 479 
disorders30, namely Wiedemann Steiner (KMT2A, MLL1)31, Kleefstra-like (KMT2C, 480 
MLL3)32, Kabuki (KMT2D, MLL2)33 syndrome, and most recently SETD1A-related 481 
disease (KMT2F)34. The physiological functions of MLL proteins are yet to be fully 482 
characterized, however, the observation that mutations in different MLL genes 483 
cause phenotypically distinct syndromes (Supplementary Table 6) suggests that 484 
each MLL protein has a unique role regulating the expression of a specific set of 485 
genes35,36. 486 
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Amongst the 4 reported MLL-gene disorders, dystonia appears unique to KMT2B-487 
related disease and is not described in other MLL syndromes (Supplementary 488 
Table 6), providing further evidence that different MLL proteins mediate the 489 
activation and transcription of a specific set of genes, with temporal and cellular 490 
context37. We utilized fibroblasts and CSF derived from patients to investigate 491 
downstream effects of KMT2B mutations on specific gene expression. The rationale 492 
for investigating THAP1 and TOR1A in the first instance was based on a number of 493 
factors, namely that (i) loss-of-function mutations in both genes cause progressive 494 
generalized dystonia with cervical, oromandibular and laryngeal symptoms, similar 495 
to those seen in KMT2B-dystonia38,39,40, (ii) both genes are expressed in fibroblasts, 496 
facilitating investigation in patient-derived tissue, (iii) analysis of methylation profiles 497 
using ENCODE demonstrates a sharp H3K4me3 peak at the 5’ region of both 498 
THAP1 and TOR1A in a wide range of cell types, including brain cells 499 
(Supplementary Fig. 7), (iv) on human brain expression profiles, THAP1 and 500 
KMT2B similarly display highest expression in the cerebellum (Fig 5b, 501 
Supplementary Fig. 8). We detected statistically significant reduced levels of 502 
THAP1 and TOR1A gene expression and THAP1 protein expression in patient 503 
fibroblasts. The mechanisms causing such alterations in KMT2B-dystonia remain 504 
yet to be elucidated. Whilst H3K4 methylation is clearly associated with the process 505 
of active transcription, several studies have shown that H3K4 methylation is 506 
required, not for absolute transcriptional output, but rather for transcription stability 507 
or consistency41. Recent studies have suggested that H3K4Me is required to 508 
minimize transcriptional variability between cells in a population, rather than 509 
absolute expression41,42, so the effects of KMT2B haploinsufficiency on 510 
THAP1/TOR1A levels could conceivably operate via an intermediary sensitive to 511 
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stochastic fluctuations. Whilst our study focuses on two genes, it is highly likely that 512 
dysregulation of other genes and proteins are also involved in the disease 513 
pathophysiology of KMT2B-dystonia. Further studies will determine whether 514 
expression profiles of other genes are affected in KMT2B-dystonia and contributory 515 
to the phenotype.  516 
CSF analysis is increasingly recognized as a highly useful tool for studying synaptic 517 
proteins and dysregulation of the dopaminergic system43. In our study, CSF 518 
immunoblotting studies revealed significant reduction of D2R protein and increase 519 
in TH levels in patients with KMT2B-dystonia when compared to control CSF 520 
samples. Downregulation of D2R could conceivably impair post-synaptic activation 521 
of coupled G-proteins with subsequent downstream effects, as seen in other 522 
inherited dystonias. Reduced D2R striatal availability is reported in patients with 523 
DYT1 and DYT6 dystonia44,45. Furthermore, D2R dysfunction is described in murine 524 
DYT1 models, where aberrant D2R-mediated responses are associated with 525 
reduced D2R protein levels and impaired G-protein activation46. The observed rise 526 
in CSF TH levels could be secondary to reduced pre-synaptic D2 autoreceptors47, 527 
which could conceivably impact dopamine synthesis and bioavailability. 528 
Interestingly patients with KMT2B-dystonia had normal CSF levels of the stable 529 
dopamine metabolite, homovanillic acid (HVA), indicating normal dopamine 530 
turnover (conversion of dopamine to HVA by monoamine oxidase and catechol-o-531 
methyl transferase). Whilst CSF HVA levels accurately reflect dopamine turnover, 532 
they are not always a true indicator of dopamine synthesis and bioavailability. Low 533 
CSF HVA levels often correlate with low dopamine levels in patients with inherited 534 
disorders of dopamine deficiency such as TH deficiency, aromatic l-amino acid 535 
decarboxylase deficiency, and many inherited pterin defects3. However HVA levels 536 
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may also be normal (autosomal dominant GTP cyclohydrolase deficiency) or 537 
elevated (Dopamine Transporter Deficiency Syndrome) in diseases known to be 538 
associated with dopamine deficiency3,48. Normal HVA levels in KMT2B-dystonia 539 
may therefore not reflect true dopamine levels. Indeed, the effect of KMT2B 540 
mutations on dopamine synthesis and bioavailability remain yet to be fully 541 
elucidated. 542 
In conclusion, we report KMT2B mutations in 27 patients with a clinically 543 
recognizable, distinct form of dystonia. To date, the underlying etiology is only 544 
genetically resolved in a minority of childhood-onset cases of dystonia, which 545 
precludes confirmatory diagnosis, accurate disease prognostication and selection of 546 
appropriate treatment strategies. We have shown that many patients with molecular 547 
confirmation of KMT2B-dystonia have significant, sustained clinical improvement 548 
with DBS and referral for DBS assessment should thus be considered for this group 549 
of individuals. Identification of additional cases will allow further characterization of 550 
the full phenotypic disease spectrum. Our report highlights mutations in KMT2B as 551 
a new and important cause of early-onset dystonia, emphasizing the crucial role of 552 
KMT2B in the control of normal voluntary movement.  553 
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 717 
Figure 1: 718 
Molecular Genetics Findings in Patients with KMT2B Mutations 719 
(a) Top panel: Schematic representation of chromosome 19. Middle panel: Ten 720 
microdeletions on 19q13.11-19q13.12 are displayed as horizontal red bars 721 
(GRCh37/Hg19). Lower panel: The smallest overlapping region comprises two genes, 722 
ZBTB32 and KMT2B. (b) Schematic of exon-intron structure of KMT2B (based on NCBI 723 
Reference Sequence: NM_014727.2) is shown indicating the location of the 7 frameshift 724 
insertions and deletions (blue, above gene), 2 stop-gain mutations (dark red, above gene), 725 
1 splice site variant (purple, below gene) and 7 missense changes (in green, below gene). 726 
(c) Alignment of KMT2B amino acid sequences from seven different species, the human 727 
paralog KMT2A (another member of the MLL protein family) and the human PHF6 protein 728 
used to model the PHD-like domain. Gly1652 (in red) is highly conserved in all listed 729 
amino acid sequences, while the Phe1662 residue (in red) is either conserved or tolerates 730 
replacement by the similar amino acid, Tyr without predicted functional effect 731 
(Supplementary Fig. 10). (d-g) Alignment of KMT2B amino acid sequences from seven 732 
different species and the human paralog KMT2A. (d) Arg1705 (in red) is conserved to 733 
zebrafish and in human KMT2A. (e) Arg1762 is fully conserved throughout species. (f) 734 
Leu1781 (in red) is conserved in all listed mammalian homologs of KMT2B. (g) Arg2517 735 
(in red) is conserved to zebrafish and in human KMT2A. (h) Alignment of KMT2B amino 736 
acid sequences from seven different species, the human paralog KMT2A and SET domain 737 
containing proteins (human SETD1A/SETD1B, yeast Set1, Dictyostelium discoideum Set1. 738 
Ile2674 (in red) is highly conserved in all listed amino acid sequences.  739 
Residues matching human KMT2B (grey), not matching (white), amino acids conserved in 740 
all representative sequences (dark grey). * positions of fully conserved residues; : 741 
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conservation between groups of strongly similar properties and . conservation between 742 
groups of weakly similar properties. 743 
Figure 2 744 
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 746 
Figure 2:  747 
Clinical Features of Patients with KMT2B Mutations 748 
(a) Patient 17, age 13 years, evidence of gait disturbance with dystonic posturing of the 749 
four limbs. (b) Patient 27, age 19 years and (c) Patient 14, age 18 years both showing 750 
bilateral upper limb dystonic posturing. (d, e) Patient 23, age 8 years with retrocollis. (f) 751 
Patient 12, age 6 years, generalized dystonia, with jaw-opening dystonia and 4-limb 752 
posturing. (g) Montage of patient faces: Top row (left to right) Patients 1, 2, 3, 4, 8, 9; 753 
Middle row (left to right) Patients 11, 12, 13, 14, 16, 17 and Bottom row (left to right) 754 
Patients 21, 23, 25, 26a, 26b, 27. Facial elongation, broad nasal base and bulbous nasal 755 
tip, particular evident in Patients 1, 2, 4, 9, 11, 12, 14, 17, 23, 25, 26a, 26b, 27.  756 
757 
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 758 
Figure 3 759 
 760 
Figure 3:  761 
Radiological Features in KMT2B-patients 762 
Magnetic resonance imaging (MRI) with T2*-weighted sequences (a-d), diffusion- imaging 763 
datasets with b-value of zero (e-h) and susceptibility weighted sequences (i-l). Abnormal 764 
findings indicated by yellow arrows. (a,e,i) Representative MRI from control subjects for 765 
T2*-weighted sequences (a: age 10y2m), diffusion-weighted sequences (e: age 10y4m) 766 
and susceptibility weighted sequences (i: age 10y8m) indicating normal appearances of 767 
basal ganglia on all three sequences. (b,f,j) Patient 1, age 9y5m, (c,g,k) Patient 13, age 768 
11y3m, (d) Patient 9, age 15y1m, (h) Patient 22 age 13y1m and (l) Patient 25, age 16y - 769 
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all show evidence of bilateral subtle hypointensity of the globus pallidus with hypointense 770 
lateral streak of globus pallidus externa.  771 
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Figure 4: 774 
Homology Modelling of KMT2B Protein Structure 775 
(a) Schematic of domain architecture of KMT2B. (b-d) The degree of amino conservation 776 
is displayed in the structural models for the different domains. Red to blue indicates 777 
increasing conservation. (b) Model of PHD-like domain shows the mutation sites Gly1652 778 
and Phe1662 (c) Model of the FYRN domain presents the position and conservation of 779 
Arg1762 and Leu1781. (d) Model of the SET methyltransferase domain indicates the 780 
position and conservation of Ile2674, Tyr2688 and Ile2694. (e) Location of Gly1652 in the 781 
PHD-like domain model and the hydrogen bond network in the vicinity are shown. Helix ⍺3 782 
is also indicated. (f) Hydrophobic packing involving Phe1662 (green) is displayed. (g) 783 
Change to leucine (green) at position 1662 is predicted to cause loss of contact within the 784 
hydrophobic core. Residue side chains are presented as spheres highlighting van der 785 
Waals contacts. (h) Interactions involving Arg1762 (green) from FYRN with Arg2463 and 786 
Leu2464 of FYRC. The hydrogen bond interactions are highlighted. (i) Leu1781 shown at 787 
the interface of FYRN (pink)/FYRC (blue) domains. The backbone hydrogen bonds 788 
stabilizing the sheet structure are highlighted. (j) Interactions involving Arg2517 (green) 789 
and WDR5 (brown). The salt bridge interaction between Arg2517 of KMT2B and Asp172 790 
of WDR5 is highlighted. (k) Location and contacts involving Ile2674 (green) in the 791 
hydrophobic core of the SET domain are exhibits. SAH is displayed in light brown. (l) 792 
Conversion to threonine (green) at position 2674 is predicted to result in loss of contacts in 793 
the core. (m) Interactions involving Tyr2688 (light green) and Ile2694 (dark green) in the 794 
core of the SET domain. The hydrogen bond between Tyr2688 and Ser2661 is 795 
highlighted. 796 
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Figure 5 797 
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Figure 5: 799 
Functional Investigation of the Downstream Effects of Mutations in KMT2B  800 
(a) PCR analysis of human fetal and adult cDNA for expression of KMT2B. KMT2B is 801 
widely expressed in a range of human tissues, including fibroblasts, brain tissue and 802 
midbrain dopaminergic neurons. (b) Box plots of KMT2B mRNA expression levels in 10 803 
adult brain regions (source: BRAINEAC; http://www.braineac.org/). The expression levels 804 
are based on exon array experiments as previously described and are plotted on a log2 805 
scale (y axis)49. This plot shows that KMT2B is ubiquitously expressed across all 10 brain 806 
regions analyzed, with expression higher in the cerebellum than in any other region. 807 
Putamen (PUTM), frontal cortex (FCTX), temporal cortex (TCTX), occipital cortex (OCTX). 808 
hippocampus (HIPP), substantia nigra (SNIG), medulla (specifically inferior olivary 809 
nucleus, MEDU), intralobular white matter (WHMT), thalamus (THAL), and cerebellar 810 
cortex (CRBL). “N” indicates the number of brain samples analyzed to generate the results 811 
for each brain region. Whiskers extend from the box to 1.53 the interquartile range. (c) 812 
Quantitative RT-PCR indicates that patients with KMT2B mutations (n=4) have 813 
significantly decreased fibroblast mRNA levels of KMT2B when compared to controls 814 
(Controls = 1.01±0.16SD, n=3 technical replicates of 2 biological samples; Patients = 815 
0.57±0.12SD, n=3 technical replicates of 4 biological samples; two-tailed unpaired t-test, 816 
p-value 0.0182). (d) Quantification of immunoblotting of tri-methyl H3K4 (left) and di-817 
methyl H3K4 (right) in histones extracted from patient-derived fibroblasts (Patient 14 and 818 
16), and two control fibroblast cell lines. Methylation values are normalized to pan-histone 819 
H3 levels. Individual data-points are plotted with center bar showing mean and error bars 820 
showing standard deviation. Differences between control and patient-derived samples are 821 
not significant (H3K4me3: Controls = 96.63±19.98SD; Patient 16 = 104.1±40.31SD; 822 
Patient 14 = 94.75±38.36SD; p=0.62; H3K4me2: Controls = 94.33±19.25SD; Patient 16 = 823 
127.8±20.79SD; Patient 14 = 80.23±31.09SD; p=0.07). n=3 fibroblast samples (technical 824 
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replicates). (e) Quantification of immunoblotting of tri-methyl H3K4 in Dictyostelium cell 825 
lysates. Tri-methyl H3K4 intensity values are normalized against levels of total histone H3. 826 
H3K4 tri-methylation is impaired in set1- cells compared to wild type. Expression of GFP-827 
DdSet1 or GFP-DdSet1(Ile1447Thr) in set1- cells rescues levels of H3K4Me3. Individual 828 
data-points are plotted with center bar showing mean and error bars showing standard 829 
deviation (Wild type = 115±48.25SD; set1- = 5.94±9.37SD; set1- GFP-DdSet1(I1447T) 1 = 830 
133.7±38.11SD; set1- GFP-DdSet1(I1447T) 2 = 129.8±42.34SD; set1- GFP-831 
DdSet1(I1447T) 3 = 96.07±31.82SD; set1- GFP-DdSet1 = 110.5±12.02SD). n=3 samples 832 
(technical replicates). (f) Quantitative RT-PCR of THAP1 and TOR1A, indicates that 833 
patients have a reduction of THAP1, and to a lesser extent of TOR1A transcripts in 834 
comparison to controls (THAP1: Controls = 1.04±0.40SD, n=3 technical replicates of 2 835 
biological samples; Patients = 0.55±0.05SD, n=3 technical replicates of 4 biological 836 
samples; two-tailed unpaired t-test, p-value 0.0498; TOR1A: Controls = 1.00±0.05SD, n=3 837 
technical replicates of 2 biological samples; Patients = 0.79±0.06SD, n=3 technical 838 
replicates of 4 biological samples; two-tailed unpaired t-test, p-value 0.0140). (g) 839 
Immunoblotting studies in fibroblasts indicate a significant reduction in THAP1 for Patient 840 
2, 13, 14 and 16 when compared to controls (Control 1 = 1.34±0.02SD; Control 2 = 1.80± 841 
0.11SD; Patient 2 = 0.83±0.06SD; Patient 13 = 0.77±0.17SD; Patient 14 = 0.53±0.04SD; 842 
Patient 16 = 0.54±0.06SD; Kruskal-Wallis test, p-value 0.0078). n=3 fibroblast protein 843 
samples (technical replicates). (h) Immunoblotting studies in fibroblasts indicate a 844 
statistically reduced level of TOR1A in Patient 14 when compared to controls (Control 1 = 845 
1.08±0.02SD; Control 2 = 1.13± 0.22SD; Patient 14 = 0.64±0.05SD; two-tailed unpaired t-846 
test, p-value 0.0196), but not for Patient 2, 13 and 16 (Patient 2 = 1.09±0.27SD; Patient 13 847 
= 1.39±0.18SD; Patient 16 = 1.13±0.29SD; Kruskal-Wallis test, p-value 0.0812). n=3 848 
fibroblast protein samples (technical replicates). (i) CSF immunoblotting studies on Patient 849 
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2 and 16 show markedly reduced levels of D2R and increased levels of TH when 850 
compared to control CSF (D2R: Controls = 1.09±0.21SD, n=4 control CSF samples 851 
(biological replicates); Patients = 0.64±0.02SD, n=2 patient CSF samples (biological 852 
replicates); two-tailed unpaired t-test, p-value 0.0471; TH: Controls = 0.52±0.08SD, n=4 853 
control CSF samples (biological replicates); Patients = 0.90±0.01SD, n=2 patient CSF 854 
samples (biological replicates); two-tailed unpaired t-test, p-value 0.0036). 855 
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Table 1a: KMT2B Mutations and Evolution of Motor Phenotype in KMT2B-dystonia 856 
Pat Age 
(y) 
 
Sex 
M/F 
KMT2B mutation(1) Symptoms at 
presentation: 
Body distribution 
& motor features 
Onset of 
dystonia 
(y) 
 
Bilateral 
LL 
involve-
ment (y) 
Bilateral 
UL 
involve-
ment (y) 
Onset of 
cranial, 
cervical, 
laryngeal 
dystonia (y) 
Symptoms of cranial, 
cervical, laryngeal 
dystonia 
Trial of medication and 
clinical response 
Deep brain stimulation 
(DBS) 
 
1 14 
M 
Deletion: Chr19: 
35,608,666- 
36,233,508 
RLL 
Right foot posturing 
Gait disturbance 
4 6 6-11 5 Dysarthria 
Dysphonia 
Swallowing difficulties 
L-dopa trial – no benefit No 
2 14 
F 
Deletion: Chr19: 
35,197,252- 
38,140,100 
Bilateral LL 
Limping 
Gait disturbance 
7 7 8-11 8 Dysarthria 
Dysphonia 
Drooling 
L-dopa trial – no benefit 
BLF – no benefit 
No 
3 9 
M 
Deletion: Chr19: 
34,697,740- 
37,084,510 
RLL 
Right foot posturing 
Gait disturbance 
2.5 3 6-7 4 Dysarthria 
Dysphonia 
Swallowing difficulties 
Drooling 
GBP – some reduction in 
tone 
No 
4 11 
F 
Deletion: Chr19: 
36,191,100- 
36,376,860 
LLL 
Left toe walking 
Gait disturbance 
4 8 9-12 m 5 Dysarthria 
Dysphonia 
Swallowing difficulties 
Drooling 
L-dopa trial– minimal 
benefit 
THP – minimal benefit 
Planned for 2016 
5 20 
M 
Deletion: Chr19: 
31,725,360- 
36,229,548 
Developmental 
delay  
Gait disturbance 
Present 
but age of 
onset not 
known 
Present 
but age of 
onset not 
known 
Present 
but age of 
onset not 
known 
Not known Nasal voice None No 
6 10 
F 
Deletion: Chr19: 
35,017,972- 
36,307,788 
RLL 
Right foot inversion 
2.5 4 4 4-7 Dysarthria/Anarthria 
Jaw-opening dystonia 
Swallowing difficulties 
NGF 6y 
PEG 8y 
Torticollis 
Severe retrocollis 
 
L-dopa trial – no benefit 
THP – no benefit 
Inserted age 7y 
Sustained excellent 
clinical benefits 3y post-
DBS, marked 
improvement in 
torticollis, retrocollis, 
manual abilities and left 
leg dystonia. Loss of 
efficacy when ‘DBS off‘ 
for almost a year and 
functional recovery 
when switched on again.  
7 21 
M 
Deletion: Chr19: 
35,414,997- 
37,579,142 
RLL 
Right foot dragging 
Gait disturbance 
7 7-8 13 13 Dysarthria 
Dysphonia 
Swallowing difficulties 
L-dopa trial – no benefit 
BLF – no benefit 
No 
857 
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 858 
Pat Age 
(y) 
 
Sex 
M/F 
KMT2B mutation(1) Symptoms at 
presentation: 
Body distribution 
& motor features 
Onset of 
dystonia 
(y) 
 
Bilateral 
LL 
involve-
ment (y) 
Bilateral 
UL 
involve-
ment (y) 
Onset of 
cranial, 
cervical, 
laryngeal 
dystonia (y) 
Symptoms of cranial, 
cervical, laryngeal 
dystonia 
Trial of medication and 
clinical response 
Deep brain stimulation 
(DBS) 
 
8 17 
F 
Deletion: Chr19: 
35,414,997- 
37,579,142 
RLL 
Right foot posturing 
4 6 4-12 2.5 Dysarthria  
Dysphonia 
Drooling 
Torticollis 
L-dopa trial – no benefit Inserted age 10y 
Good response over 6 
years, particularly 
evident after 
replacement of faulty 
right DBS lead 
9 14 
M 
Deletion: Chr19: 
35,967,904- 
37,928,373 
Bilateral LL 
Gait disturbance 
4 4 9-13 9 Dysarthria 
Dysphonia 
L-dopa trial – possible initial 
benefit but not sustained 
Inserted age 14y 
Very good clinical 
response at 4m post 
DBS with restoration of 
independent ambulation 
10 7 
F 
Deletion: Chr19: 
35,794,775- 
38,765,822 
Bilateral LL 
Intermittent toe 
walking 
Gait disturbance 
4 4 - - - None No 
11 25 
F 
c.399_400insT 
p.Pro134Serfs*24 
RUL 
Right Hand Cramps 
and Posturing  
6 12 12 14(2)  Anarthria  
Orolingual dystonia  
Tongue thrusting 
Swallowing difficulties  
PEG 
L-dopa trial – poorly 
tolerated, no benefit 
 
Being considered 
12 6 
F 
 
c.1690C>T 
p.Arg564* 
Bilateral LL 
Toe walking 
4 5 6 5 Dysarthria 
Swallowing difficulties 
L-dopa trial – no benefit No 
13 11 
M 
c.3026_3027del 
p.Glu1009Glyfs*9 
 
Bilateral UL 
Posturing, tremor 
Difficulty handwriting 
8 9-10 8 9 Dysarthria  
Dysphonia 
 
L-dopa trial – no benefit No 
14 18 
M 
c.3143_3149del 
p.Gly1048Glufs*132 
 
Bilateral UL 
Posturing of hands 
Myoclonic jerks 
8 13 8 13 Dysarthria  
Dysphonia 
Swallowing difficulties 
L-dopa trial – no benefit No 
15 20 
F 
c.4545C>A 
p.Tyr1515* 
Bilateral LL 
Toe Walking  
Clumsy 
 
 
2 9 9 8.5 Dysarthria  
Dysphonia 
Oromandibular dystonia 
Swallowing difficulties 
PEG 18y 
Moderate responses to 
(and currently taking)  
THP 
CLZ 
L-dopa 
BLF 
No 
859 
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 860 
Pat Age 
(y) 
 
Sex 
M/F 
KMT2B mutation(1) Symptoms at 
presentation: 
Body distribution 
& motor features 
Onset of 
dystonia 
(y) 
 
Bilateral 
LL 
involve-
ment (y) 
Bilateral 
UL 
involve-
ment (y) 
Onset of 
cranial, 
cervical, 
laryngeal 
dystonia (y) 
Symptoms of cranial, 
cervical, laryngeal 
dystonia 
Trial of medication and 
clinical response 
Deep brain stimulation 
(DBS) 
 
16 6 
F 
c.4688del 
p.Ala1563Aspfs*83 
Bilateral LL 
Increasing falls 
Gait disturbance 
3 3 5 6 Dysarthria  
Dysphonia 
L-dopa trial – no benefit 
THP – initial benefit, not 
sustained 
No 
17 17 
M 
c.6515_6518delins 
p.Val2172Alafs*11. 
Bilateral LL 
Toe walking 
Gait disturbance 
1 1 8 12 Dysarthria  
Dysphonia 
Swallowing difficulties 
L-dopa trial – no benefit 
TBZ – no benefit 
BLF and THP – mild benefit 
Inserted age 16y 
Very good clinical 
response 4m post-DBS 
with restoration of 
independent ambulation 
18 20 
F 
c.8061del 
p.Tyr2688Thrfs*50 
Clumsy movements 
Difficulties with 
speech articulation  
1 - - Infancy Dysarthria 
Dysphonia 
Swallowing and 
chewing difficulties 
No No 
19 28 
M 
c.8076del 
p.Ile2694Serfs*44 
Bilateral LL 
Toe walking 
Severe speech 
delay  
2 3 4 (L>R) 7 Anarthria 
Jaw opening dystonia 
Tongue protrusion 
Swallowing difficulties 
PEG 8y 
L torticollis,R laterocollis 
L-dopa trial – no benefit 
THP and TBZ reduced 
tongue protrusion  
Inserted age 27y 
Improvement of jaw 
opening dystonia and 
tongue protrusion  
20 40 
M 
c.3528+2T>A LLL 
Gait disturbance  
L foot dragging  
Clumsiness 
4 5 8 10 Severe dysarthria  
Dysphonia 
L Torticollis 
L-dopa trial – no benefit 
TBZ, THP, SUL – no 
benefit 
 
Inserted age 32y – no 
benefit. Electrode 
replaced in 2009 with 
sustained improvement 
in foot posture but only 
transient benefit to 
cervical, UL and LL 
dystonia.  
21 18 
M 
c.4955G>A 
p.Gly1652Asp 
RLL 
Right leg posturing 
 
6 8 12 5 Dysarthria  
Dysphonia 
Swallowing difficulties 
L-dopa trial – no benefit 
THP – not tolerated 
Inserted age 15y 
Sustained clinical 
benefit 3y post-DBS, 
improved dystonia and 
independent walking 
22 20 
F 
c.4986C>A 
p.Phe1662Leu 
RLL 
Right foot posturing 
Abnormal gait 
5 8 5-13 5-6 Dysarthria  
Dysphonia 
Swallowing difficulties 
Torticollis 
L-dopa trial – no benefit 
BLF – no benefit 
THP – low dose, mild 
benefit 
BTX neck – reduction in 
pain but no functional 
Inserted age 20y 
Very good clinical 
response 9m post DBS 
with improved dystonia 
and independent 
walking 
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benefit 
 861 
Pat Age 
(y) 
 
Sex 
M/F 
KMT2B mutation(1) Symptoms at 
presentation: 
Body distribution 
& motor features 
Onset of 
dystonia 
(y) 
 
Bilateral 
LL 
involve-
ment (y) 
Bilateral 
UL 
involve-
ment (y) 
Onset of 
cranial, 
cervical, 
laryngeal 
dystonia (y) 
Symptoms of cranial, 
cervical, laryngeal 
dystonia 
Trial of medication and 
clinical response 
Deep brain stimulation 
(DBS) 
 
23 8  
M 
c.5114G>A 
p.Arg1705Gln 
Bilateral LL 
Toe-walking 
3 3 6 6.5 Dysarthria 
Torticollis 
L-dopa trial – no benefit 
CLZ, THP, IT BLF – some 
benefit 
 
Inserted age 7y with 
considerable benefit 
24  27 
F 
c.5284C>T 
p.Arg1762Cys 
LLL 
Tiptoe walking and 
in-turning of L foot 
6 6 7  7 Dysarthria  
Anarthria from 14-15y  
Reduced tongue 
movements  
Swallowing preserved 
L-dopa trial – no benefit 
THP- no benefit  
No 
25 19 
F 
c.5342T>C 
p.Leu1781Pro 
RLL 
Right foot posturing 
Gait disturbance 
8 12 13 10 Dysarthria  
Dysphonia 
Swallowing difficulties 
Torticollis 
L-dopa trial – no benefit 
LVT – mild benefit 
Inserted age 19y 
Very good clinical 
response 4m post-DBS 
with improved dystonia 
and ambulation(3) 
26a 8 
M 
c.7549C>T 
p.Arg2517Trp 
Delayed speech 
Delayed motor 
development 
 
- - - 8 Severe paroxysmal 
retrocollis and jaw 
dystonia 
- No 
26b 46 
F 
c.7549C>T 
p.Arg2517Trp 
Bilateral UL  
UL posturing 
Torticollis 
Inability to walk long 
distances and run 
23  26 23 23 Dysphonia  
Torticollis 
None No 
27 19 
F 
c.8021T>C 
p.Ile2674Thr 
RUL 
Posturing, tremor 
Difficulty handwriting 
Myoclonic jerks 
9 11-13 10 9-10 Dysphonia L-dopa trial – no benefit 
THP – no benefit 
LVT – no benefit 
CBZ – initial benefit, not 
sustained 
CLZ – not tolerated 
No 
BLF: baclofen; BTX: botulinum toxin; CLZ: clonazepam; GBP: gabapentin; IT: intrathecal; LL: lower limbs; LLL: left lower limb; LVT: levetiracetam; m: months; NGF: nasogastric feeding; 862 
Pat: patient; PEG: percutaneous endoscopic gastrostomy; RLL: right lower limb; RUL: right upper limb; SUL: sulpiride; UL: upper limbs; TBZ: tetrabenzine; THP: trihexyphenidyl; y: years 863 
(1)
 based on NCBI Reference Sequence: NM_014727.2 864 
(2)
 onset shortly after being fitted with orthodontic braces 865 
(3)
 had undergone 2 posterior cranial fossa explorations and palatal surgery before DBS 866 
KMT2B Dystonia 
Meyer et al 2016 
 
 
Table 1b: Additional Clinical Features in KMT2B-patients 867 
Patient KMT2B mutation Number of 
genes in 
microdeletion 
Intellectual 
disability 
Dysmorphic 
features 
Additional 
neurological 
features 
Psychiatric 
features 
Abnormal skin 
features 
Other systemic 
manifestations 
1 Deletion: Chr19: 
35,608,666-36,233,508 
38 Mild Elongated face Not reported Not reported Not reported Not reported 
2 Deletion: Chr19: 
35,197,252- 38,140,100 
124 No Elongated face 
Bulbous nasal tip 
Not reported Not reported Not reported Not reported 
3 Deletion: Chr19: 
34,697,740 -37,084,510 
109 Moderate Elongated face Not reported Not reported Cutis aplasia(1) Retinal dystrophy 
4 Deletion: Chr19: 
36,191,100-36,376,860 
14 V mild - subtle 
memory problems  
Elongated face 
Broad nasal bridge 
Bulbous nasal tip 
Not reported Prone to 
anxiety(2) 
Not reported Not reported 
5 Deletion: Chr19:  
31,725,360-36,229,548 
110 Moderate Sparse hair 
Blepharophimosis 
Absent eyelashes of 
lower eyelids 
Low set, posteriorly 
rotated ears 
Epicanthic folds 
Narrow nasal 
bridge, ridge and 
point 
Largely bifid tongue 
 Micrognathia 
Teeth overcrowding 
Finger contractures 
5th finger 
clinodactyly  
Toe over-riding  
Dysplastic toenails 
Microcephaly Not reported Occipital cutis aplasia  Small echogenic 
kidneys with low 
GFR, required renal 
transplant at 17 
years 
6 Deletion: Chr19: 
35,017,97-36,307,788 
69 No Not  
reported 
Microcephaly Not reported Not reported Not reported 
7 Deletion: Chr19: 
35,414,997-37,579,142 
99 Mild Elongated face Absence seizures Not reported Not reported Absent right testis 
8 Deletion: Chr19: 
35,414,997-37,579,142 
99 Mild 5th finger 
clinodacytly 
Not reported Not reported Ectodermal dysplasia Not reported 
9 Deletion: Chr19: 
35,967,904-37,928,373 
79 Mild Elongated face Strabismus Not reported Not reported Cleft palate 
10 Deletion: Chr19: 
35,794,775-38,765,822 
111 Moderate Not reported Strabismus  Not reported Not reported Short stature 
Bronchiectasis 
 868 
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Patient KMT2B mutation Number of 
genes in 
microdeletion 
Intellectual 
disability 
Dysmorphic 
features 
Additional 
neurological 
features 
Psychiatric 
features 
Abnormal skin 
features 
Other systemic 
manifestations 
11 c.399_400insT 
p.Pro134Serfs*24 
- No Bulbous nasal tip Not reported Not reported Not reported Not reported 
12 c.1690C>T 
p.Arg564* 
- Moderate Elongated face 
Bulbous nasal tip, 
short nasal root, 
Hypertelorism, large 
mouth with full 
lower lip 
Epilepsy Not reported Not reported Not reported 
13 c.3026_3027del 
p.Glu1009Glyfs*9 
- V mild - difficulties 
with attention 
Elongated face Not reported Not reported Not reported Not reported 
14 c.3143_3149del 
p.Gly1048Glufs*132 
- No Elongated face 
Bulbous nasal tip 
Not reported Not reported Not reported Not reported 
15 c.4545C>A 
p.Tyr1515* 
- No Elongated face 
Bulbous nasal tip 
Not reported Not reported Not reported Not reported 
16 c.4688del 
p.Ala1563Aspfs*83 
- No Elongated face Not reported Not reported Not reported Not reported 
17 c.6515_6518delins 
p.Val2172Alafs*11. 
- No Elongated face Not reported Not reported Phimosos 
 
Short stature 
18 c.8061del 
p.Tyr2688Thrfs*50 
- Mild Micrognathia 
Atrophic tongue 
Bulbous nasal tip 
5th finger 
clinodacytly 
Not reported Not reported Not reported Not reported 
19 c.8076del 
p.Ile2694Serfs*44 
- No 
 
Short stature Delay in saccade 
initiation and 
hypometric vertical 
saccades 
ADHD(3) with no 
response to 
Ritalin 
Not reported Not reported 
20 c.3528+2T>A - Moderate 
6y- verbal IQ 74 
Performance IQ 
87 
No cognitive 
decline 
Not reported Not reported Not reported Not reported Not reported 
21 c.4955G>A 
p.Gly1652Asp 
- Mild Elongated face Not reported Not reported Not reported Short stature 
Hypertrichosis 
22 c.4986C>A 
p.Phe1662Leu 
- No Elongated face 
Bulbous nasal tip 
Not reported Not reported Not reported Not reported 
869 
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 870 
 871 
Patient KMT2B mutation Number of 
genes in 
microdeletion 
Intellectual 
disability 
Dysmorphic 
features 
Additional 
neurological 
features 
Psychiatric 
features 
Abnormal skin 
features 
Other systemic 
manifestations 
23 c.5114G>A 
p.Arg1705Gln 
- Mild-moderate  
6y WISC-IV 50-60 
Elongated face 
Bulbous nasal tip 
Broad philtrum, 
Upslanted eyes, 
epicanthus, low-set 
ears, periorbital 
fullness, gap 
between front teeth 
Spasticity in lower 
limbs from 6y  
Not reported Ichtyotic skin lesions 
with criss-cross 
pattern under the feet 
and at knees, broad 
scarring after 
operation 
Episodic vomiting 
24 c.5284C>T 
p.Arg1762Cys 
- No Short stature Oculomotor apraxia 
with difficulty 
initiating saccades. 
Mild spasticity 
No Not reported Not reported 
25 c.5342T>C 
p.Leu1781Pro 
- No Elongated face 
Bulbous nasal tip 
Not reported Not reported Not reported Not reported 
26a c.7549C>T 
p.Arg2517Trp 
- No Bulbous nasal tip None ADHD(3) 
Currently on 
methyphenidate,  
oxazepam, 
risperidone 
Not reported Not reported 
26b c.7549C>T 
p.Arg2517Trp 
- No Bulbous nasal tip Idiopathic 
intracranial 
hypertension – on 
acetazolamide 
None Not reported Not reported 
27 c.8021T>C 
p.Ile2674Thr 
- V subtle mild 
learning difficulties 
Bulbous nasal tip Not reported Anxiety 
Self-harm 
behavior 
Depression 
Obsessive-
compulsive 
traits(4) 
Not reported Not reported 
 872 
(1) Supplementary Figure 3c  873 
(2)
 Identified on formal psychology review 874 
(3) Diagnosed by psychiatrist and under regular psychiatry review 875 
(4) Under regular review with psychiatrist (ICD-10-CM F06.30; ICD-10-CM F42) 876 
ADHD: attention deficit hyperactivity disorder; GFR: glomerular filtration rate; V: very; y: years 877 
